IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 87.85

Change

+0.47 (+0.54)%

Market Cap

N/A

Volume

0.13M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-16 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.56 (+0.40%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.35 (+0.52%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.50 (+0.47%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.22 (+1.34%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.02 (-0.09%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.17 (-0.56%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.41 (+0.43%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.13 (+0.45%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.19 (+0.32%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.42 (-1.89%)

USD 8.55M

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.97 % 0.00 %

+0.64 (+0.46%)

USD 1.40B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

+0.23 (+0.46%)

CAD 0.54B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.19% 43% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.19% 43% F 66% D+
Trailing 12 Months  
Capital Gain -0.44% 24% F 30% F
Dividend Return 1.46% 88% B+ 23% F
Total Return 1.02% 24% F 23% F
Trailing 5 Years  
Capital Gain 24.20% 62% D 63% D
Dividend Return 7.73% 79% B- 23% F
Total Return 31.94% 71% C- 58% F
Average Annual (5 Year Horizon)  
Capital Gain 5.70% 67% D+ 53% F
Dividend Return 6.65% 67% D+ 49% F
Total Return 0.96% 74% C 24% F
Risk Return Profile  
Volatility (Standard Deviation) 13.19% 81% B- 72% C
Risk Adjusted Return 50.43% 81% B- 64% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike